Drugs · acquisition-cost intelligence
ZOMIG
zolmitriptan· ingredient zolmitriptanSelective serotonin (5HT1) agonists· ZOLMITRIPTAN 2.5 mg/1; ZOLMITRIPTAN 5 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$43.97
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 8 weeks.
2025-01-202026-05-20
Same-ingredient options by acquisition cost
Other zolmitriptan products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Zolmitriptan | $1.25 | −$42.72 |
| zolmiptriptan | $2.72 | −$41.25 |
| Zolmitriptan | $43.97 | +$0.00000 |
Medicare Part D coverage · CY2026
On 8 plan formularies · typical tier 4
Prior auth 13% · Step therapy 25% · Quantity limit 100% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.